ReproNovo has appointed Mark Altmeyer as Chairman of the Board of Directors.
Bringing over 35 years of experience to the role, Altmeyer was most recently Founder and CEO of Arvelle Therapeutics.
His other former roles include Chief Commercial Officer at Axovant and senior commercial and general management positions at Bristol Myers Squibb and Otsuka.
As well as holding non-executive or independent director roles at several life science companies, Altmeyer is currently the Chairman of AM-Pharma and Calluna Pharma.
Jean Marie Duvall, CEO and Co-Founder of ReproNovo, said: “Mark has successfully guided companies through critical development and strategic inflection points, capabilities that will be highly valuable as we globally advance RPN-001 and RPN-002 across four indications in fertility and women’s health.”
Altmeyer said: “ReproNovo is addressing critical therapeutic gaps in areas that have seen limited innovation, despite these being really large markets. I look forward to working with the Board and management team to maximise these highly differentiated products, create value and ultimately bring these products to patients.”